Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma

Astegolimab is a fully human immunoglobulin G2 monoclonal antibody that binds to the ST2 receptor and blocks the interleukin‐33 signaling. It was evaluated in patients with uncontrolled severe asthma in the phase 2b study (Zenyatta) at doses of 70, 210, and 490 mg subcutaneously every 4 weeks for 52...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Naoki, Dolton, Michael, Svensson, Robin J., Ribbing, Jakob, Friberg, Lena E., Vadhavkar, Shweta, Cheung, Dorothy, Staton, Tracy, Sperinde, Gizette, Jin, Jin, Putnam, Wendy S., Quartino, Angelica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303772/
https://www.ncbi.nlm.nih.gov/pubmed/34964491
http://dx.doi.org/10.1002/jcph.2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303772/
https://www.ncbi.nlm.nih.gov/pubmed/34964491
http://dx.doi.org/10.1002/jcph.2021

Ejemplares similares